AlphAIAlphAI — Financial news for AI agents
marketplace.orgOCT 212 min read$ABT

Abbott Laboratories announces a baby formula spinoff company

Abbott Laboratories plans to spin off its nutrition business, including Similac and Ensure, into a separate publicly traded company. The move aims to focus each entity on its respective market. Analysts note the spinoff may help Abbott manage legal risks and concentrate on healthcare. The company faces ongoing litigation over alleged links between its formulas and a fatal illness in preterm babies.

Original reporting
marketplace.org
Published Oct 21, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Laboratories announces a baby formula spinoff company — source image
Source · marketplace.org
Decision brief

The 30-second read

$ABTBearishHigh
01

Why it matters

The announcement separates consumer nutrition from core medical businesses, potentially improving focus but also exposing the spin‑off to litigation risk.

02

Market read

First‑report spin‑off news for a large‑cap health‑care company, likely to move ABT and create a new tradable entity.

03

What to watch

Potential regulatory scrutiny and ongoing litigation may affect the new entity more than the parent.

Relevance 7/10Novelty 8/10Timing: today

Background

Abbott is a diversified health‑care company with pharmaceuticals, medical devices, diagnostics, and nutrition products.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott Laboratories announced a spin‑off of its nutrition business (Ensure, Similac) into a separate publicly traded company.

Expected impact

likely modest downside pressure on ABT as investors price out the nutrition segment and potential liability.

Evidence & confidence

Spin‑offs typically cause the parent stock to trade lower while the new entity may attract interest; the announcement is fresh and material.

Market effects

Sector

May prompt re‑valuation of other diversified health‑care firms with consumer‑goods exposure.

Regional

U.S. healthcare sector could see slight re‑balancing as Abbott sheds a consumer segment.

Global

Limited to investors tracking large‑cap U.S. health‑care stocks.

Counterpoint

What could challenge this read

The spin‑off could unlock value if the nutrition business thrives independently, offsetting any short‑term ABT weakness.

Key entities

  • company
    Abbott Laboratories

    U.S.-listed health‑care conglomerate announcing the spin‑off.

Read at source← All news

StoryAbbott Laboratories to spin off its nutrition business into a standalone public company

Also covered by

3 outlets

Related articles

OCT 23
$ABTMedAI 8/10

Abbott’s colorectal cancer test shows improved sensitivity

Abbott (NYSE: ABT) presented data at the European Society for Medical Oncology Congress showing its Oncodetect test for colorectal cancer recurrence achieved 72.2% sensitivity, outperforming its previous version. The study analyzed 279 patients, detecting additional cases with the new test. Patients with detectable ctDNA had higher recurrence risk and lower survival rates. The test is not FDA-approved and is performed at Genomic Health Inc.

investing.com2 min
OCT 23
$ABTMedAI 8/10

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Abbott (NYSE: ABT) presented data at ESMO 2026 showing its Oncodetect® test improved sensitivity for detecting colorectal cancer recurrence by 30% compared to its previous test. The study found a 10.6-fold higher recurrence risk for patients with detectable ctDNA. Abbott aims to connect innovations across cancer care, from early detection to post-treatment monitoring.

prnewswire.com2 min
OCT 22
$ABTMed

ABT Maintained by RBC Capital -- Price Target Lowered to $125

RBC Capital maintained an 'Outperform' rating on Abbott Laboratories (ABT) but lowered its price target from $130 to $125. GuruFocus values ABT at $135.74, suggesting a 24.9% undervaluation. The company has a GF Score of 82/100, indicating strong financial health and growth potential, but insiders have sold $46.85M in shares over the past three months.

gurufocus.com2 min
OCT 22
$ABTMed

Abbott plans nutrition spinoff as Q3 sales improve

Abbott plans to spin off its nutrition division by the end of 2027. Q3 sales improved 5.1% to $2.26B, but YTD sales fell 1.3%. The new company will include brands like Ensure and Similac, with 16,000 employees. Abbott's CEO cited changing consumer preferences as a driver for the separation.

nutraingredients.com2 min
OCT 22
$ABTMedAI 8/10

Mizuho reiterates Neutral on Abbott Labs stock, keeps $115 target

Mizuho maintained a Neutral rating and $115 target for Abbott Labs (ABT), citing segment challenges and operational headwinds. ABT reported Q3 2026 earnings of $1.42 per share, meeting estimates, with revenue at $13.01B. The company lowered full-year sales guidance and plans to spin off its Nutrition business by 2027. BTIG cut its target to $125 but kept a Buy rating.

investing.com2 min
OCT 22
$ABTMed

Abbott to spin-off nutrition into standalone business

Abbott Laboratories plans to spin off its nutrition business, which has $8.5bn in annual sales, into a standalone publicly traded company by the end of 2027. The move aims to address different investment profiles and growth strategies. Abbott's Q3 and nine-month results show a 1.3% decline in nutrition sales but a 11.9% increase in total group sales. The company recently settled lawsuits related to infant formula recalls for $385m and $670m.

finance.yahoo.com2 min